Literature DB >> 263496

The use of coronal sections in evaluating lesions of the sellar and parasellar regions.

N T Wolfman, M Boehnke.   

Abstract

Nine cases from a series of 12 are presented to illustrate the value of coronal sections in delineating the borders and origins of extraaxial sellar and parasellar masses. In this projection, the presence or absence of suprasellar extension is demonstrated, and two important signs are discussed. A rim of cisternal cerebrospinal fluid termed the "cap" is seen over the superior border of masses extending into the suprasellar region defining their extraaxial location. The broad base of a lesion will define its origin. The limitations of the method are also discussed.

Mesh:

Year:  1978        PMID: 263496     DOI: 10.1097/00004728-197807000-00013

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  5 in total

1.  Practical co-table for direct coronal CT scanning.

Authors:  A Zieger; H Simon; G Düsterbehn
Journal:  Neurosurg Rev       Date:  1989       Impact factor: 3.042

2.  Presentation and management of parasellar and suprasellar metastatic mass lesions.

Authors:  J C Kattah; R M Silgals; H Manz; J G Toro; A Dritschilo; F P Smith
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-01       Impact factor: 10.154

3.  Diagnosis of sellar and parasellar lesions by computed tomography.

Authors:  A Hatam; M Bergström; T Greitz
Journal:  Neuroradiology       Date:  1979-12-12       Impact factor: 2.804

4.  Macroprolactinomas: CT evaluation of reduction of tumor size after medical treatment.

Authors:  G Scotti; G Scialfa; S Pieralli; P G Chiodini; B Spelta; D Dallabonzana
Journal:  Neuroradiology       Date:  1982       Impact factor: 2.804

5.  Neuroradiological manifestations of suprasellar pituitary adenomas, meningiomas and craniopharyngiomas.

Authors:  Y Numaguchi; T Kishikawa; J Ikeda; M Fukui; K Kitamura; Y Tsukamoto; K Hasuo; K Matsuura
Journal:  Neuroradiology       Date:  1981-03       Impact factor: 2.804

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.